Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMDX, unsubscribe in one click. Privacy
IMDX reported $17.8M in cash and short-term investments (as of Jun 30, 2026) and used about $8.5M/quarter in operations, an estimated runway of 6.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 62 · High
The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events tha10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMDX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMDX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →